Hubei Goto BiopharmLtd Past Earnings Performance
Past criteria checks 0/6
Hubei Goto BiopharmLtd's earnings have been declining at an average annual rate of -38.9%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 2% per year.
Key information
-38.9%
Earnings growth rate
-45.2%
EPS growth rate
Biotechs Industry Growth | 11.3% |
Revenue growth rate | 2.0% |
Return on equity | -1.6% |
Net Margin | -2.5% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Shares Fly 42% But Investors Aren't Buying For Growth
Oct 09Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%
May 12Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear
May 02Lacklustre Performance Is Driving Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Low P/S
Feb 28Revenue & Expenses Breakdown
How Hubei Goto BiopharmLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 547 | -14 | 62 | 40 |
30 Jun 24 | 532 | 0 | 61 | 37 |
31 Mar 24 | 569 | 23 | 56 | 37 |
31 Dec 23 | 566 | 23 | 55 | 38 |
30 Sep 23 | 543 | 23 | 54 | 46 |
30 Jun 23 | 604 | 31 | 50 | 49 |
31 Mar 23 | 604 | 31 | 49 | 47 |
01 Jan 23 | 605 | 40 | 47 | 45 |
30 Sep 22 | 592 | 64 | 39 | 42 |
30 Jun 22 | 557 | 64 | 41 | 41 |
31 Mar 22 | 570 | 76 | 41 | 39 |
01 Jan 22 | 591 | 78 | 41 | 37 |
30 Sep 21 | 595 | 76 | 36 | 35 |
30 Jun 21 | 569 | 76 | 29 | 28 |
31 Mar 21 | 573 | 71 | 27 | 26 |
31 Dec 20 | 468 | 53 | 21 | 22 |
31 Dec 19 | 465 | 73 | 23 | 26 |
31 Dec 18 | 437 | 71 | 17 | 27 |
31 Dec 17 | 334 | 47 | 19 | 23 |
Quality Earnings: 300966 is currently unprofitable.
Growing Profit Margin: 300966 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300966 is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.
Accelerating Growth: Unable to compare 300966's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300966 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).
Return on Equity
High ROE: 300966 has a negative Return on Equity (-1.61%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/25 09:45 |
End of Day Share Price | 2024/12/25 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Goto Biopharm Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|